Analysts see $ -0.19 EPS for MediWound Ltd. (MDWD)


<! –

Market News


November 8, 2018 – Vivian Park

Analysts expect MediWound Ltd. (NASDAQ: MDWD) reported on November 15 on $ -0.19 EPS. They envisage a 0.03 euro change in EPS or 18.75 percent since the last quarter of -0.16 euros EPS. After the expiration of 0.15 euros EPS, analysts of MediWound Ltd. they see a 26.67% EPS increase. At the last trading session, inventory declined by 0.17%. $ 0.01, reaching $ 5.79. Around 31,842 shares were traded or 17.18% more than the average. MediWound Ltd. (NASDAQ: MDWD) increased by 13.04% from 8 November 2017 and is rising. The S & P500 reached 2.58% less.

MediWound doo (NASDAQ: MDWD) coverage of credit ratings

Among the 2 analysts covering Mediwound (NASDAQ: MDWD), 2 had a Buy, 0 Sell, and 0 Hold rating. Therefore, they are 100% positive. Mediwound had 3 analytical reports from 10 May 2018 according to SRatingsIntel. Stock MediWound Ltd. (NASDAQ: MDWD) has a "Buy" rating, which Oppenheimer gave on Thursday, May 10. On Monday, June 11, Oppenheimer retained him with a "Buy" and $ 1400 rating.

MediWound doo, an integrated biopharmaceutical company, focuses on the development, production and marketing of new therapeutic products in Israel. The company has a market capital of 157.37 million dollars. NexoBrid, a biopharmaceutical product for the removal of eschar, dead or damaged tissue in adults with heat burns with deep partial and full thickness. He currently has a negative earnings. The company also develops EscharEx, which is in clinical trials II. Phases for decomposition of chronic and other hard-wound wounds.

The next recent and important news from MediWound Ltd. (NASDAQ: MDWD) was published by, which published an article entitled "MediWound for hosting the third quarter of 2018 the financial results of the conference call on November 13 at 8:30 Eastern time" on November 7, 2018.

MediWound Ltd. (NASDAQ: MDWD) Ratings Chart

Receive news and reviews via email – Enter your email below to receive a condensed daily summary of the latest news and analyst estimates with our free daily newsletters.

Vivian Park

Source link